Wednesday, March 4, 2015

Biotech Investing: Clinical Updates from Threshold (THLD) and Arqule (ARQL)

Both Threshold (THLD) and Arqule (ARQL) reported earnings in the last day and both provided updated guidance on the time of top line pivotal trial results of their pancreatic and liver cancer, respectively.

Threshold now expects results from its phase 3 pancreatic cancer trial in the first quarter of 2016.  Prior guidance was "sometime" in 2016 so now we are look at the front end of the year providing a closer trading catalyst.  The trial is being conducted by its partner Merck.

Arqule now expects results from its phase 3 liver cancer trail in the fourth quarter of 2015.  Previous guidance was the first quarter of 2016 but recruitment has been better than expected.

I have 6,000 shares of Threshold and don't plan to sell until we get closer to the pancreatic readout.  I may actually add to my position via selling naked puts.

I just sold my shares in Arqule earlier this week after it made a strong run these past few weeks after presentations at investor conferences.  I plan to get back in when/if it goes back below $1.70 per share.

Do your own research and good luck!

No comments:

Post a Comment

Thank you for your contribution to BiotechInvestor.com